ENDRA Life Sciences Inc. (NASDAQ:NDRA) CTO Michael Milos Thornton sold 18,750 shares of the firm’s stock in a transaction that occurred on Monday, March 29th. The shares were sold at an average price of $2.37, for a total transaction of $44,437.50. Following the transaction, the chief technology officer now directly owns 274,960 shares in the company, valued at approximately $651,655.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.
Michael Milos Thornton also recently made the following trade(s):
- On Wednesday, April 7th, Michael Milos Thornton sold 15,000 shares of ENDRA Life Sciences stock. The shares were sold at an average price of $2.53, for a total value of $37,950.00.
Shares of NDRA stock opened at $2.51 on Thursday. ENDRA Life Sciences Inc. has a 12 month low of $0.60 and a 12 month high of $3.10. The company has a quick ratio of 3.19, a current ratio of 3.42 and a debt-to-equity ratio of 0.10. The business’s 50 day moving average is $2.49 and its two-hundred day moving average is $1.42. The company has a market cap of $104.42 million, a PE ratio of -1.36 and a beta of 1.60.
Several institutional investors have recently made changes to their positions in NDRA. Worth Venture Partners LLC acquired a new stake in shares of ENDRA Life Sciences in the fourth quarter worth $247,000. HN Saltoro Capital LP acquired a new stake in shares of ENDRA Life Sciences in the fourth quarter worth $145,000. K.J. Harrison & Partners Inc grew its stake in shares of ENDRA Life Sciences by 60.9% in the fourth quarter. K.J. Harrison & Partners Inc now owns 277,629 shares of the company’s stock worth $208,000 after acquiring an additional 105,129 shares during the last quarter. Renaissance Technologies LLC acquired a new stake in shares of ENDRA Life Sciences in the fourth quarter worth $65,000. Finally, Virtu Financial LLC boosted its stake in ENDRA Life Sciences by 62.5% during the third quarter. Virtu Financial LLC now owns 41,738 shares of the company’s stock worth $31,000 after buying an additional 16,057 shares in the last quarter. Institutional investors and hedge funds own 2.84% of the company’s stock.
Separately, Zacks Investment Research downgraded ENDRA Life Sciences from a “buy” rating to a “hold” rating in a report on Wednesday, January 20th.
ENDRA Life Sciences Company Profile
ENDRA Life Sciences Inc develops technology for clinical diagnostic ultrasound. It develops thermo-acoustic enhanced ultrasound technology that transmits sound waves, which bounce off tissues, organs, and blood for the treatment of nonalcoholic fatty liver disease, as well as temperature monitoring of thermoablative surgery, vascular imaging, and tissue perfusion.
Recommended Story: How to Trade Using Analysts Ratings
Receive News & Ratings for ENDRA Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ENDRA Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.